Plain-English translation of NCT06628947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called KIO-301 that is injected directly into both eyes to help people with late-stage retinitis pigmentosa—a condition where the light-sensing cells in the retina slowly break down, causing progressive vision loss. Researchers want to find out if the medication is safe and whether it can help slow the progression of vision loss. You would receive three injections over 12 weeks and then be monitored for an additional 12 weeks.
Retinitis pigmentosa currently has no cure and causes progressive blindness. This trial exists to test whether this new treatment could offer hope to people with advanced disease who have already lost significant vision.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive three injections into both of your eyes—one injection every 6 weeks over a 12-week treatment period. You would visit the clinic every 3 weeks during treatment and for another 12 weeks after your last injection (about 30 weeks total) so doctors can check your safety and measure any changes in your vision. Blood tests and eye examinations will be part of your regular clinic visits. If you receive a placebo (inactive treatment) in the main study, you may have the option to receive the actual treatment in an additional 24-week extension phase.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Australia